Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes

Elicio Therapeutics (ELTX), a clinical-stage biotech company developing immunotherapies for KRAS-driven cancers, was added to the Russell 2000 and Russell 3000 indexes as of June 26, 2026. The company is advancing its lead candidate ELI-002 7P, an off-the-shelf cancer immunotherapy targeting common KRAS mutations. However, the Phase 2 AMPLIFY-7P trial did not meet its primary endpoint of disease-free survival, prompting Elicio to refine its Phase 3 development strategy and initiate a Phase 1 study in metastatic pancreatic cancer.